James Lamar
Optometrist · New Orleans, LANPI 1346654126
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,350 of the $44,743 with a category attached, or 67.8%. Biotissue Holdings Inc. accounts for 82.9% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $36,482, more than ten times the $1,666 reported in 2019. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $231.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$37K
- Alcon$2K
- Optos, Inc.$827
- AbbVie$823
- Glaukos Corporation$675
- Tarsus Pharmaceuticals, Inc.$402
- plus $3K from 16 others
What the payments were for
- Consulting fees$30,35068%
- Travel & lodging$5,27712%
- Food & beverage$8,51319%
- Entertainment$6031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 60 | $37,090 |
| Alcon | 27 | $2,328 |
| Optos, Inc. | 6 | $827 |
| AbbVie(2 entities) | 17 | $823 |
| Glaukos Corporation | 7 | $675 |
| Tarsus Pharmaceuticals, Inc. | 15 | $402 |
| Johnson & Johnson Vision Care, Inc. | 6 | $397 |
| Novartis | 14 | $304 |
| Dompe US, Inc. | 4 | $293 |
| Mallinckrodt Hospital Products Inc. | 6 | $276 |
| Oyster Point Pharma, Inc. | 6 | $250 |
| Sun Pharmaceutical Industries Inc. | 7 | $197 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $150 |
| Coopervision Inc. | 4 | $149 |
| Bausch & Lomb Americas Inc. | 4 | $149 |
| Carl Zeiss Meditec USA, Inc. | 1 | $132 |
| Alimera Sciences, Inc. | 1 | $94 |
| Apellis Pharmaceuticals, Inc. | 1 | $77 |
| Harrow Eye, LLC | 1 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $35 |
| Ocular Therapeutix, Inc. | 1 | $29 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$26,778
- AmnioGraft$7,895
- AIR OPTIX$1,096
- PANORAMIC OPHTHALMOSCOPE$701
- DAILIES$642
- OCT OPHTHALMOSCOPE$575
- NFC-700$350
- Oxervate$244
- VUITY$242
- TOTAL30$226
- P200DTx$225
- P200T$225
- P200TE$225
- P200TxE$225
- ACTHAR$210
- Precision 1$207
- iDose$172
- Acuvue$150
- iStent inject Trabecular Micro-Bypass Stent System$138
- RESTASIS MULTIDOSE$134
How this compares
$44,743 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $718,459 |
| XiidraLifitegrast | 18 | $14,953 |
| RestasisCyclosporine | 22 | $13,027 |
| Cyclosporine | 14 | $5,760 |
| Fluorometholone | 80 | $4,737 |
| Prednisolone Acetate | 61 | $1,955 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $1,111 |
| Latanoprost | 96 | $902 |
| Brimonidine Tartrate | 15 | $333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $293 | $718,45913 claims |
| Bausch & Lomb Americas Inc.Xiidra | $149 | $14,95318 claims |
| AbbVieRestasis | $823 | $13,02722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in New Orleans
- Breanne McGheeNew Orleans$14K
- Jeanne HermanNew Orleans$7K
- Ashley DelcambreNew Orleans$6K
- Lynh Chi NguyenNew Orleans$5K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.